Ascendis Pharma A/S - American Depositary Shares (ASND)
142.32
-7.77 (-5.18%)
NASDAQ · Last Trade: Apr 4th, 6:03 PM EDT
Detailed Quote
Previous Close
150.09
Open
145.34
Bid
141.84
Ask
142.53
Day's Range
139.57 - 147.49
52 Week Range
111.09 - 169.37
Volume
576,851
Market Cap
8.13B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
450,890
Chart
About Ascendis Pharma A/S - American Depositary Shares (ASND)
Ascendis Pharma is a biotechnology company focused on developing innovative medicines using its proprietary TransCon technology platform. The company aims to address unmet medical needs, particularly in the areas of endocrine diseases and rare disorders, by creating optimally dosed therapies that enhance the bioavailability and efficacy of existing therapies. Through its robust pipeline, Ascendis Pharma is committed to advancing new treatment options that improve patient outcomes and quality of life, leveraging its expertise in drug development and deep understanding of biological mechanisms. Read More
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.
